Phio Pharmaceuticals Corp.
PHIO
$1.09
$0.010.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 12.58% | -25.68% | -36.76% | -42.47% | -47.18% |
| Gross Profit | -12.58% | 25.68% | 36.76% | 42.47% | 47.18% |
| SG&A Expenses | 10.81% | 0.34% | -7.33% | -14.25% | -18.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.68% | -14.15% | -24.23% | -30.95% | -35.77% |
| Operating Income | -11.68% | 14.15% | 24.23% | 30.95% | 35.77% |
| Income Before Tax | -7.20% | 18.33% | 27.86% | 33.96% | 36.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.20% | 18.33% | 27.86% | 33.96% | 36.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.20% | 18.33% | 27.86% | 33.96% | 36.38% |
| EBIT | -11.68% | 14.15% | 24.23% | 30.95% | 35.77% |
| EBITDA | -11.83% | 13.89% | 23.92% | 30.61% | 35.54% |
| EPS Basic | 81.87% | 83.88% | 79.06% | 81.21% | 79.51% |
| Normalized Basic EPS | 81.41% | 83.62% | 78.83% | 81.08% | 80.02% |
| EPS Diluted | 81.87% | 83.88% | 79.06% | 81.21% | 79.52% |
| Normalized Diluted EPS | 81.41% | 83.62% | 78.83% | 81.08% | 80.02% |
| Average Basic Shares Outstanding | 570.28% | 591.21% | 431.55% | 240.32% | 226.98% |
| Average Diluted Shares Outstanding | 570.28% | 591.21% | 431.55% | 240.32% | 226.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |